Adagene's Muzastotug Shows Strong Efficacy and Favorable Safety in Combination Therapies for HCC and MSS CRC

summarizeSummary

Adagene reported positive interim Phase 1b/2 clinical data for muzastotug in combination therapies for HCC and MSS CRC, showing improved efficacy and a favorable safety profile at AACR 2026.

check_boxKey Events

• Positive HCC Clinical Data

  In a Phase 1b/2 study for hepatocellular carcinoma (HCC), the triple combination of muzastotug + atezolizumab + bevacizumab achieved a 66.7% overall response rate (ORR) compared to 32.5% for the control arm, with a median progression-free survival (mPFS) of 8.2 months versus 5.5 months.

• Encouraging MSS CRC Clinical Data

  For microsatellite stable colorectal cancer (MSS CRC), a Phase 1b/2 study of muzastotug + pembrolizumab + fruquintinib showed dose-dependent ORRs of 25% (10 mg/kg arm) and 40% (15 mg/kg arm).

• Favorable Safety Profile

  Both triple combination regimens were well-tolerated, with safety data comparable to the respective control arms or known monotherapy profiles, highlighting muzastotug's ability to reduce peripheral toxicity.

• Validation of Masking Technology

  The data further supports muzastotug's masked anti-CTLA-4 SAFEbody technology, which aims to improve efficacy by allowing high-dose anti-CTLA-4 therapy specifically within the tumor microenvironment without worsening systemic toxicity.

auto_awesomeAnalysis

Adagene presented new, positive interim data from two Phase 1b/2 studies of its lead asset, muzastotug, at AACR 2026. The triple combination therapy demonstrated significantly higher overall response rates (ORR) and improved progression-free survival (PFS) in hepatocellular carcinoma (HCC) compared to the control arm, while maintaining a comparable safety profile. In microsatellite stable colorectal cancer (MSS CRC), the triple combination showed dose-dependent responses with no new safety signals. These results are highly encouraging, validating muzastotug's differentiated masked CTLA-4 mechanism which aims to uncouple efficacy from typical anti-CTLA-4 toxicity. The favorable safety profile, combined with enhanced efficacy in difficult-to-treat cancers, significantly de-risks the program and supports its potential as a backbone combination therapy, which could drive future development and partnership opportunities.